Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EBP | Q15125 | 5/20 | 0.42 |
| ▸ | DHCR7 | Q9UBM7 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223858 | 1.00 | NPSR1 (0.46) | NPSR1KMT2AMEN1MAPK1RAPGEF4 | |
| SCHEMBL4108812 | 0.79 | NPSR1 (0.51) | NPSR1KMT2AMEN1MAPK1RAPGEF4 | |
| SCHEMBL4001419 | 0.79 | NPSR1 (0.51) | NPSR1KMT2AMEN1MAPK1RAPGEF4 | |
| SCHEMBL12574213 | 0.75 | ALDH1A1 (0.50) | NPSR1KMT2AALDH1A1 | |
| SCHEMBL6845966 | 0.75 | ALDH1A1 (0.50) | NPSR1KMT2AALDH1A1 | |
| SCHEMBL6845965 | 0.75 | ALDH1A1 (0.50) | NPSR1KMT2AALDH1A1 | |
| SCHEMBL3215402 | 0.72 | GAA (0.45) | NPSR1KMT2AMEN1MAPK1RAPGEF4 | |
| SCHEMBL4399065 | 0.70 | EBP (0.49) | NPSR1KMT2AALDH1A1GAAEBP | |
| SCHEMBL6642037 | 0.69 | L3MBTL1 (0.61) | NPSR1KMT2AALDH1A1GAA | |
| SCHEMBL6642041 | 0.69 | L3MBTL1 (0.61) | NPSR1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100063282-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063282-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063282-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | US | disclosed |
| EP-2136634-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009015067-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008124665-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124665-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063282-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof | NR3C1, MC2R, NR3C2 | NPSR1 198/4885KMT2A 4081/4885MEN1 1017/4885 |
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, MC2R, NR3C2 | NPSR1 181/4885KMT2A 4414/4885MEN1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.